These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 15725090

  • 1. Impact of chimaerism analysis and kinetics on allogeneic haematopoietic stem cell transplantation outcome after conventional and reduced-intensity conditioning regimens.
    Michallet AS, Fürst S, Le QH, Dubois V, Praire A, Nicolini F, Thomas X, Rafii H, Gebuhrer L, Michallet M.
    Br J Haematol; 2005 Mar; 128(5):676-89. PubMed ID: 15725090
    [Abstract] [Full Text] [Related]

  • 2. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Michallet M, Le QH, Mohty M, Prébet T, Nicolini F, Boiron JM, Esperou H, Attal M, Milpied N, Lioure B, Bordigoni P, Yakoub-Agha I, Bourhis JH, Rio B, Deconinck E, Renaud M, Chir Z, Blaise D.
    Exp Hematol; 2008 May; 36(5):535-44. PubMed ID: 18346838
    [Abstract] [Full Text] [Related]

  • 3. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT).
    Michallet AS, Nicolini F, Fürst S, Le QH, Dubois V, Hayette S, Bourgeot JP, Tremisi JP, Thomas X, Gebuhrer L, Michallet M.
    Bone Marrow Transplant; 2005 Mar; 35(6):601-8. PubMed ID: 15756285
    [Abstract] [Full Text] [Related]

  • 4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors.
    Teshima T, Matsuo K, Matsue K, Kawano F, Taniguchi S, Hara M, Hatanaka K, Tanimoto M, Harada M, Nakao S, Abe Y, Wake A, Eto T, Takemoto Y, Imamura M, Takahashi S, Ishida Y, Kanda Y, Kasai M, Takaue Y.
    Br J Haematol; 2005 Aug; 130(4):575-87. PubMed ID: 16098073
    [Abstract] [Full Text] [Related]

  • 7. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma.
    Doocey RT, Toze CL, Connors JM, Nevill TJ, Gascoyne RD, Barnett MJ, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Shepherd JD, Sutherland HJ, Voss NJ, Smith CA, Song KW.
    Br J Haematol; 2005 Oct; 131(2):223-30. PubMed ID: 16197454
    [Abstract] [Full Text] [Related]

  • 8. Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes.
    Lim ZY, Pearce L, Ho AY, Barber L, Ingram W, Usai M, Tobal K, Devereux S, Pagliuca A, Mufti GJ.
    Br J Haematol; 2007 Aug; 138(4):517-26. PubMed ID: 17608767
    [Abstract] [Full Text] [Related]

  • 9. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP, Chen CS, Tai BC, Hwang WY, Tan LK, Ng HY, Linn YC, Koh MB, Goh YT, Tan B, Lim S, Lee YM, Tan KW, Liu TC, Ng HJ, Loh YS, Mow BM, Tan DC, Tan PH.
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
    [Abstract] [Full Text] [Related]

  • 10. Reduced-intensity conditioning regimen using low-dose total body irradiation before allogeneic transplant for hematologic malignancies: Experience from the European Group for Blood and Marrow Transplantation.
    Belkacémi Y, Labopin M, Hennequin C, Hoffstetter S, Mungai R, Wygoda M, Lundell M, Finke J, Aktinson C, Lorchel F, Durdux C, Basara N.
    Int J Radiat Oncol Biol Phys; 2007 Feb 01; 67(2):544-51. PubMed ID: 17141976
    [Abstract] [Full Text] [Related]

  • 11. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
    Tong XZ, Li J, Tan EX, Zhang GC, Wu XY, Peng AH, Zheng D, Zou WY, Hong WD, Luo SK.
    Zhonghua Zhong Liu Za Zhi; 2006 Jul 01; 28(7):545-8. PubMed ID: 17147125
    [Abstract] [Full Text] [Related]

  • 12. Lineage-specific engraftment and outcomes after T-cell-depleted peripheral blood stem cell transplant with Flu/Cy/TBI conditioning.
    Montero A, Savani BN, Kurlander R, Read EJ, Leitman SF, Childs R, Solomon SR, Barrett AJ.
    Br J Haematol; 2005 Sep 01; 130(5):733-9. PubMed ID: 16115130
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors.
    Conrad R, Remberger M, Cederlund K, Ringdén O, Barkholt L.
    Haematologica; 2008 Feb 01; 93(2):265-72. PubMed ID: 18245651
    [Abstract] [Full Text] [Related]

  • 16. Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies.
    Alessandrino EP, Bernasconi P, Colombo AA, Caldera D, Malcovati L, Troletti D, Vanelli L, Varettoni M, Montanari F, Lazzarino M.
    Bone Marrow Transplant; 2004 Dec 01; 34(12):1039-45. PubMed ID: 15516936
    [Abstract] [Full Text] [Related]

  • 17. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
    Mori T, Aisa Y, Watanabe R, Yamazaki R, Kato J, Shimizu T, Shigematsu N, Kubo A, Yajima T, Hibi T, Ikeda Y, Okamoto S.
    Biol Blood Marrow Transplant; 2008 Jun 01; 14(6):651-7. PubMed ID: 18489990
    [Abstract] [Full Text] [Related]

  • 18. The influence of cyclosporin alone, or cyclosporin and methotrexate, on the incidence of mixed haematopoietic chimaerism following allogeneic sibling bone marrow transplantation for severe aplastic anaemia.
    McCann S, Passweg J, Bacigalupo A, Locasciulli A, Locatelli F, Ryan J, Schrezenmeier H, Lawler M.
    Bone Marrow Transplant; 2007 Jan 01; 39(2):109-14. PubMed ID: 17173053
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Reduced intensity of BuCy conditioning regimen for transplantation in the treatment of malignant hematologic diseases].
    Chen H, Lu DP, Huang XJ, Liu KY, Xu LP, Han W, Ren HY, Chen YH, Liu DH, Lu J, Jiang Q.
    Zhonghua Xue Ye Xue Za Zhi; 2005 May 01; 26(5):273-6. PubMed ID: 15949287
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.